By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Revance Therapeutics, Inc. 

7555 Gateway Boulevard

Newark  California  94560  U.S.A.
Phone: 510-742-3400 Fax: 510-742-3401


SEARCH JOBS

Revance is a specialty biopharmaceutical company focused on the development, manufacturing and commercialization of novel botulinum toxin products for multiple aesthetic and therapeutic indications. The company is leveraging its proprietary portfolio of botulinum toxin compounds combined with its patented TransMTS® peptide delivery system to address unmet needs in the large and growing neurotoxin markets. Revance's proprietary TransMTS technology enables delivery of botulinum toxin A through two novel drug product candidates, a needle-free topical form and an injectable form that may localize the drug to the site of injection resulting in a more targeted and potentially longer lasting delivery. Revance is pursuing clinical development for drug product candidates topical RT001 and injectable RT002 in a broad spectrum of aesthetic and therapeutic indications. The company holds worldwide rights for all indications of RT001, RT002 and the TransMTS technology platform.


Key Statistics


Email: jobs@revance.com
Ownership: Public

Web Site: Revance Therapeutics
Employees:
Symbol: RVNC
 









Company News
Revance Therapeutics, Inc. (RVNC) To Initiate Two Key Trials For RT001, Its Topical Botulinum Toxin Type A Investigational Drug Product Candidate 6/3/2015 7:23:08 AM
Revance Therapeutics, Inc. (RVNC) To Participate In Upcoming Investor Conferences 5/21/2015 1:59:19 PM
Revance Therapeutics, Inc. (RVNC) Releases First Quarter 2015 Financial Results 5/14/2015 8:01:41 AM
Revance Therapeutics, Inc. (RVNC) To Release First Quarter 2015 Financial Results Wednesday, May 13, 2015 4/30/2015 8:20:48 AM
ReVance Therapeutics, Inc. (RVNC) Releases Fourth Quarter And Full Year 2014 Financial Results And Reiterates 2015 Outlook 3/3/2015 7:57:26 AM
ReVance Therapeutics, Inc. (RVNC) Appoints Dr. Philip Vickers To Its Board Of Directors 2/27/2015 7:40:47 AM
ReVance Therapeutics, Inc. (RVNC) Announces Participation In Cowen and Company 35th Annual Health Care Conference 2/18/2015 8:21:36 AM
ReVance Therapeutics, Inc. (RVNC) To Release Fourth Quarter And Full Year 2014 Financial Results And Host Conference Call On Monday, March 2, 2015 2/13/2015 7:56:33 AM
ReVance Therapeutics, Inc. (RVNC) Defines Clinical Program Milestones And Provides Financial Guidance For 2015 1/12/2015 7:24:52 AM
ReVance Therapeutics, Inc. (RVNC) Announces Publication of Positive Results From RT002 Phase 1/2 Study 1/9/2015 7:24:35 AM
12345
//-->